What Is It?
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). By stimulating the pituitary to release growth hormone in a physiologic pattern, it may influence body composition. The FDA-approved tesamorelin product (Egrifta / Egrifta SV) is specifically indicated for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved for general weight loss, athletic performance, or anti-aging use. Any other use represents an off-label decision that requires careful provider review.
What May It Support?
- Body composition (being evaluated in select settings)
- Reduction of excess abdominal fat in FDA-approved patient population
- Adjunctive support in a broader provider-directed plan
Which Programs May Include It?
Where It Fits
Binds pituitary GHRH receptors to stimulate endogenous growth hormone release in a pulsatile, physiologic pattern.
Do I Need Bloodwork?
Regular follow-up with IGF-1 monitoring and periodic metabolic labs at intervals determined by the provider.
Likely baseline panel may include: CBC, CMP, A1c, Lipid panel, IGF-1, TSH, Pregnancy test when applicable
Important Safety Information
Common side effects may include:
- Injection-site reactions
- Joint pain (arthralgia)
- Muscle pain (myalgia)
- Fluid retention or peripheral edema
- Numbness or tingling in the extremities
- Elevated blood glucose
May cause or worsen glucose intolerance and hyperglycemia
Fluid retention, including carpal tunnel syndrome
Hypersensitivity reactions have been reported
Drug interactions: May interact with corticosteroids, thyroid hormone, insulin, and other medications that affect glucose metabolism. Provider should review the complete medication list before prescribing.
Contraindications:
- Active malignancy
- Disruption of the hypothalamic-pituitary axis (e.g., hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma)
- Pregnancy
- Known hypersensitivity to tesamorelin or mannitol
Regulatory Status
Tesamorelin (Egrifta / Egrifta SV) is FDA-approved for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is specifically not indicated for weight-loss management. Any other use is off-label.
Frequently Asked Questions
Is tesamorelin FDA-approved for weight loss?
Do I need bloodwork before starting?
Can I take tesamorelin if I have a history of cancer?
How long is treatment continued?
Consultation
Treatment is not automatically provided. A licensed medical provider must review your history, symptoms, medications, laboratory results, and treatment goals before determining eligibility.